Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of KalVista Pharmaceuticals (NASDAQ: KALV) are up over 175% premarket after the company reported positive topline data from its Phase 2 clinical trial of KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) attacks.
KalVista’s stock price is trading at $43 premarket, up 175.46%.
“We are very excited to share this positive data which shows that KVD900 is the first oral therapy to achieve clinical efficacy results comparable to current injectable therapies, while also demonstrating a promising safety and tolerability profile,” commented Andrew Crockett, CEO of KalVista.
The Phase 2 randomised, double-blind, placebo-controlled crossover clinical trial evaluated the efficacy and safety of KVD900 as an on-demand treatment for HAE attacks. The trial enrolled 53 adult HAE patients at 25 clinical sites in the United States and Europe, Including type 1 and 2 HAE patients who had three attacks in 90 days before enrollment.
The data found that:
“Today’s data show that KVD900 halts HAE attack progression and also provides rapid relief by shortening the time to symptom resolution,” said Dr Emel Aygören-Pürsün, Principal Investigator for the KVD900 Phase 2 Clinical Trial and Head of the HAE Center at the University Hospital Frankfurt.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .